• LAST PRICE
    0.1300
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0970 / 0.1300
  • Day Range
    Low 0.0970
    High 0.1300
  • 52 Week Range
    Low 0.0556
    High 1.2500
  • Volume
    1,942
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 0.096
TimeVolumeSCPS
11:03 ET3430.097
11:20 ET4210.097
03:28 ET10000.11232
04:00 ET1000.13
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesSCPS
Scopus Biopharma Inc
2.0M
-0.2x
---
United StatesATRX
Adhera Therapeutics Inc
2.2M
-0.3x
---
United StatesRASP
Rasna Therapeutics Inc
1.8M
-0.8x
---
United StatesPBLA
Panbela Therapeutics Inc
1.8M
0.0x
---
United StatesCMXC
Cell MedX Corp
1.8M
-2.0x
---
United StatesCTTH
CTT Pharmaceutical Holdings Inc
1.8M
-0.3x
---
As of 2023-02-01

Company Information

Scopus BioPharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of its immuno-oncology programs. The Company’s Duet Platform relies on an immuno-oncology with a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) within the tumor microenvironment, while alleviating tumor immunosuppression to jump-start T cell-mediated immune responses. The Duet Platform is comprised of three bifunctional oligonucleotides that consists of a toll-like receptor 9 (TLR9) agonist linked with a signal transducer and activator of transcription 3 (STAT3) inhibitor, which include CpG-STAT3siRNA (DUET-01), CpG-STAT3ASO (DUET-02) and CpG-STAT3decoy (DUET-03). The Company is developing DUET-01 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. Its pipeline also includes MRI-1867, which is a cannabinoid receptor mediating compound for the treatment of systemic sclerosis.

Contact Information

Headquarters
420 Lexington Ave Rm 300NEW YORK, NY, United States 10170-0399
Phone
212-479-2513
Fax
302-655-5049

Executives

Chairman of the Board, Principal Executive Officer
Joshua Lamstein
Vice Chairman of the Board, Treasurer, Secretary
Robert Gibson
President - Immuno-Oncology and President and Chief Executive Officer of Duet BioTherapeutics
Alan Horsager
Executive Chairman of Scopus BioPharma Israel Ltd
Aharon Schwartz
Director
Ira Greenspan

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$2.0M
Revenue (TTM)
$0.00
Shares Outstanding
21.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-0.81
Book Value
$0.19
P/E Ratio
-0.2x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.